Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Operating Leases (2023 - 2025)

Silence Therapeutics' Operating Leases history spans 2 years, with the latest figure at $71000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases changed N/A to $71000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $71000.0, a N/A change, with the full-year FY2025 number at $71000.0, changed N/A from a year prior.
  • Operating Leases hit $71000.0 in Q4 2025 for Silence Therapeutics, down from $97000.0 in the prior quarter.
  • Over the last five years, Operating Leases for SLN hit a ceiling of $264981.1 in Q1 2023 and a floor of $71000.0 in Q4 2025.